TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Teva Pharmaceutical Industries (TEVA) shares gained 19.4% over the past month, largely attributable to investor optimism surrounding its strategic pivot towards a branded drug portfolio, despite a 1% constant currency decline in Q2 sales due to generics softness. The company's innovative branded drugs, Austedo, Ajovy, and Uzedy, posted strong collective sales growth of 26% year-over-year in Q2, with Austedo alone projected to exceed $2.5 billion annually by 2027. While Teva faces ongoing headwinds in its generics segment and potential future revenue cliffs, its strengthening biosimilar pipeline, cost efficiencies, debt reduction efforts, and recent credit rating upgrades are positioning the company for clearer long-term growth, making its current valuation attractive relative to industry peers.

Analysis

Teva Pharmaceutical Industries (TEVA) is exhibiting a strategic pivot that has garnered positive investor sentiment, evidenced by a 19.4% stock price increase over the past month. This optimism persists despite mixed second-quarter results, where the company beat earnings estimates but missed on sales, which declined 1% on a constant currency basis. The market is focusing on the robust growth within Teva's innovative branded drug portfolio, where sales for Austedo, Ajovy, and Uzedy collectively rose 26% year-over-year in Q2. Specifically, Austedo sales grew 29% to $891 million in the first half of 2025, with a long-term revenue target exceeding $2.5 billion by 2027. This growth is offsetting persistent weakness in the global generics business, which faces competitive pressure and the impact of a divestiture in Japan, leading the company to guide 2025 total revenues toward the lower end of its $16.8-$17.2 billion range. Key headwinds remain, including a high debt load, a potential 2026 revenue cliff for generic Revlimid, and the selection of Austedo for IRA Medicare price negotiations beginning in 2027. However, the company's strengthening biosimilar pipeline, with plans to double sales by 2027, and recent credit outlook upgrades from major rating agencies suggest a clearer path to long-term growth and margin improvement.

Key Decisions for Investors

• Investors should weigh the significant long-term growth potential from the branded drug portfolio, particularly Austedo, and the expanding biosimilar pipeline against the persistent short-term weakness in the traditional generics segment.
• Monitor key upcoming catalysts that could de-risk the investment, including the progress of the duvakitug Phase III trial with Sanofi, the successful launch of five additional biosimilars by 2027, and management's execution on cost savings to achieve its 30% adjusted operating margin target.
• Be cautious of future revenue headwinds, specifically the 2026 patent cliff for generic Revlimid and the impact of IRA Medicare price negotiations on Austedo starting in 2027, which could temper long-term growth projections.
• Consider the current valuation, which at a forward P/E of 7.11 is below the industry average but above its own 5-year mean, suggesting that while the stock may appear inexpensive, some of the turnaround is already being priced in by the market.